Moleculin Biotech Inc
Performance History
| Key Stats | |
|---|---|
| Open | $0.59 |
| Prev. Close | $0.58 |
| EPS | -0.89 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 10, 2023 |
| Dividend Yield % | - |
| Market Cap | $17.14M |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 0.55 | 0.59 |
| 52 Week Range | 0.33 | 1.65 |
| Ratios | |
|---|---|
| P/B Ratio | 0.49 |
| Revenue | - |
| Operating M. % | 0.00% |
| Earnings | -$26.27M |
| Earnings Growth % | - |
| EBITDA Margin % | - |
| ROE % | -56.16% |
| EPS | -0.89 |
Score Breakdown
All Score (55 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| MBRX | Market | |
|---|---|---|
| Value | 85 | 42 |
| Quality | 41 | 46 |
| Ownership | 9 | 39 |
| Growth | 48 | 44 |
| Dividends | - | 32 |
All Score (55 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Moleculin Biotech Inc (MBRX)
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Walter V. Klemp
- Headquarters
- Houston
- Employees
- 15
Keep an eye on Moleculin Biotech Inc
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.